Copertina

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
di: Jeffrey D. Sharon, et al.
Pubblicazione: (2024)

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
di: Ghader Mohammadnezhad, et al.
Pubblicazione: (2024)

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )
di: Charly Gaul, et al.
Pubblicazione: (2025)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
di: Nathaniel M. Schuster, et al.
Pubblicazione: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
di: Stephen D. Silberstein, et al.
Pubblicazione: (2024)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
di: Emmanuelle A. D. Schindler, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
di: Serena Laura Orr, et al.
Pubblicazione: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

The role of stress in the comorbidity of migraine and other chronic primary pain
di: Shi‐Jie Zhao, et al.
Pubblicazione: (2025)

Microneedles for the treatment of migraine and orofacial pain: A narrative review
di: Baicheng Cao, et al.
Pubblicazione: (2026)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
di: Dawn C. Buse, et al.
Pubblicazione: (2025)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
di: Gerlinde Freimark, et al.
Pubblicazione: (2025)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
di: Susan Hutchinson, et al.
Pubblicazione: (2026)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine
di: Marie Raquin, et al.
Pubblicazione: (2025)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
di: Christoph T. Berger, et al.
Pubblicazione: (2026)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine ( TEAM) study
di: Gregory A. Panza, et al.
Pubblicazione: (2024)

Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham‐controlled study
di: Nan Cheng, et al.
Pubblicazione: (2025)

Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project
di: Larry Charleston
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
di: Stephen Silberstein, et al.
Pubblicazione: (2026)

The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model
di: Philip Victor Reducha, et al.
Pubblicazione: (2024)

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial
di: Stefanie Lysk, et al.
Pubblicazione: (2025)

Efficacy of an educational website on headaches in schoolchildren: A cluster‐randomized controlled trial
di: Henrike Goldstein, et al.
Pubblicazione: (2025)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
di: Andrew Blumenfeld, et al.
Pubblicazione: (2024)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
di: Keshet Pardo, et al.
Pubblicazione: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
di: Todd J. Schwedt, et al.
Pubblicazione: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
di: Samantha C. Shao, et al.
Pubblicazione: (2024)